Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis

Anushka Bhaskar, Anna Oh, William Shomali, Gabriel Mannis, Michaela Liedtke, Jason Gotlib, Tait Shanafelt, Bita Fakhri

Blood (2025) 146 (Supplement 1): 6308.

https://doi.org/10.1182/blood-2025-6308

Published: 2025

Journal Articles

Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16

Blood (2025) 146 (Supplement 1): 1474.

https://doi.org/10.1182/blood-2025-1474

Published: 2025

Journal Articles

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Eytan Stein, Alice Mims, Zhuoer Xie, Gabriel Mannis, Justin Watts, Farhad Ravandi, Gary Schiller, Brian Ball, Hongtao Liu, Jessica Altman, Eunice Wang, J. Jean Cui, Jihao Zhou, Zachary Zimmerman, Stephen Strickland

Blood (2025) 146 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2025-1655

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

Blood (2025) 146 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2025-2525

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 6.

https://doi.org/10.1182/blood-2025-6

Published: 2025

Journal Articles

Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia

Woo In Cho, Ritika Dutta, Kyle Cobarrubias, Emily Inlow, Noel Adre, Nichole Olson, Kristen Cunanan, Vivek Charu, Asiri Ediriwickrema, Tian Zhang, Gabriel Mannis

Blood (2025) 146 (Supplement 1): 8256.

https://doi.org/10.1182/blood-2025-8256

Published: 2025

Journal Articles

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Gabriel Mannis, Nikolai Podoltsev, Deepa Jeyakumar, Justin Watts, Pankit Vachhani, Brian Jonas, Uma Borate, Eric Tam, Harry Erba, Yuling Shi, Donna Haney, William Rice, Rafael Bejar, Naval Daver

Blood (2025) 146 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2025-1645

Published: 2025

Journal Articles

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Eric Kuo, Veronica Santiago, Kailee Tanaka, Vikram Puram, Crystal Zhou, Jesse W. Tai, Gabriel Mannis, Ravindra Majeti, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2023-187644

Published: 2023

Journal Articles

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

Edna Cheung, Claire Schumann, Tian Y. Zhang, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 5927.

https://doi.org/10.1182/blood-2023-185524

Published: 2023

Journal Articles

A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform

Joseph Wagner, Markus D. Lacher, Christine J. Gu, Christopher Leonardi, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 5952.

https://doi.org/10.1182/blood-2023-186953

Published: 2023

Journal Articles

Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia

Jesse W. Tai, Guan Li, Kailee Tanaka, Jayakrishnan Gopakumar, Crystal Zhou, Miles Hamilton Linde, Alejandro Villar-Prados, Athreya S Rangavajhula, Aaron C Trotman-Grant, Niklas Landberg, Amy C Fan, Gabriel Mannis, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 1335.

https://doi.org/10.1182/blood-2023-187981

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients

Maria Moscvin, Matthew Schwede, Gabriel Mannis, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4231.

https://doi.org/10.1182/blood-2023-186672

Published: 2023

Journal Articles

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

Ruwan Gunaratne, Crystal Zhou, Jesse W. Tai, Matthew Schwede, Kailee Tanaka, Matthew Alkaitis, Raymond Yin, Brian J. Sworder, Gabriel Mannis, Ravindra Majeti, Michael S. Khodadoust, David M. Kurtz, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 4307.

https://doi.org/10.1182/blood-2023-181459

Published: 2023

Journal Articles

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Matthew Schwede, Gladys Rodriguez, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Eran Bendavid, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 958.

https://doi.org/10.1182/blood-2023-187725

Published: 2023

Journal Articles

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Riya Sinha, Matthew Schwede, Ben Viggiano, David Kuo, Solomon Henry, Douglas Wood, Gabriel Mannis, Ravindra Majeti, Jonathan Chen, Tian Y. Zhang

Blood (2023) 142 (Supplement 1): 960.

https://doi.org/10.1182/blood-2023-190151

Published: 2023

Journal Articles

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Emma C St. Martin, Matthew Schwede, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Tian Y. Zhang, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2023-190614

Published: 2023

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis

Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia

Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy

Phase 1b/2 Trial of Enasidenib in Lower-Risk MDS and Nonproliferative CMML without Isocitrate Dehydrogenase Type 2 Mutations

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform

Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients

Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data

Harnessing Artificial Intelligence for Risk Stratification in Acute Myeloid Leukemia (AML): Evaluating the Utility of Longitudinal Electronic Health Record (EHR) Data Via Graph Neural Networks

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only